News & Media | Iambic Therapeutics

NEWS & MEDIA

Read our recent announcements

Press

June 22, 2026

Bayer and Iambic collaborate to advance drug discovery with AI

Press

Announcement

April 8, 2024

Podcast Discusses New Advances for Iambic's Clinical Oncology Study and its AI-Driven Drug Discovery Platform

Publication

April 8, 2024

Validation of a Novel Type II HER2 Inhibitor Through Preclinical Studies Across Various Cancer Models (AACR 2024 Poster)

Press

Announcement

April 5, 2024

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

Press

Presentation

Announcement

March 28, 2024

Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting

Press

Announcement

March 27, 2024

Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors

Press

Announcement

March 18, 2024

Iambic’s Rapid Path to the Clinic Enabled by Its AI-Driven Drug Discovery Platform, Built in Collaboration with NVIDIA

Publication

February 23, 2024

Iambic Therapeutics Announces New Research with Cover Article in Nature Machine Intelligence Demonstrating the Capabilities of its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

Press

Announcement

February 14, 2024

Iambic says new AI model bests AlphaFold as protein models rocket ahead

Press

Announcement

February 12, 2024

Iambic Therapeutics Announces New Research with Cover Article in Nature Machine Intelligence Demonstrating the Capabilities of its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

Bayer and Iambic collaborate to advance drug discovery with AI

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Iambic to participate in upcoming investor conferences

Iambic to Participate in April Investor Conferences

Iambic to Participate in March Investor Conferences

February 9, 2026

Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules

IAM1363-01: A Phase 1/1b Study of a Selective and Brain-Penetrant HER2 Inhibitor for HER2-Driven Solid Tumors

Validation of a Novel Type II HER2 Inhibitor Through Preclinical Studies Across Various Cancer Models (AACR 2024 Poster)

February 23, 2024

Iambic Therapeutics Announces New Research with Cover Article in Nature Machine Intelligence Demonstrating the Capabilities of its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

Entos (Now Iambic) in Collaboration with Caltech and NVIDIA: Advances in geometric deep learning for computational chemistry in Proceedings of the National Academy of Science USA

November 15, 2021

#COVIDisAirborne: AI-enabled multiscale computational microscopy of delta SARS-CoV-2 in a respiratory aerosol

January 13, 2026

JPM Healthcare Conference 2026 Company Presentation

October 30, 2025

Promise & Reality: Decoding AI’s Impact On Drug Development

October 28, 2025

From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery

September 23, 2025

Enchant: A Multi-Modal Transformer Model to Break Down the Data Wall between Preclinical and Clinical Research and Development

September 22, 2025

Leveraging AI/ML to Engineer Next-Generation HER2 Inhibitors with Enhanced Selectivity and Brain Penetrance

September 10, 2025

Predictive Drug Discovery with Enchant v2

August 18, 2025

Iambic will present new preclinical NSCLC data for IAM1363, a potent Type II HER2 inhibitor, at #WCLC25

August 11, 2025

Fireside chat at the KeyBanc Capital Markets Technology Leadership Forum

Video: Iambic CEO Tom Miller Interview at the NASDAQ MarketSite

Let's work together

Leverage the Iambic discovery process for your program. Reach out to us at partnerships@iambic.ai.